1521 Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer: a joint analysis of the REGOMUNE and REGONIVO studies

Documenti analoghi

• 1521 Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer: a joint analysis of the REGOMUNE and REGONIVO studies
  di: Kohei Shitara, et al.
  Pubblicazione: (2023-11-01)
• 1519 Avelumab combined with regorafenib in solid tumors with tertiary lymphoid structures: a phase 2 REGOMUNE trial cohort
  di: Antoine Adenis, et al.
  Pubblicazione: (2023-11-01)
• Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide
  di: Maud Toulmonde, et al.
  Pubblicazione: (2024-02-01)
• Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab
  di: Maud Toulmonde, et al.
  Pubblicazione: (2025-06-01)
• 782-G The correlation of tumor immune microenvironment with response to neoadjuvant chemotherapy response in undifferentiated pleiomorphic sarcomas: an analysis of the NEOSARCOMICS study
  di: Jean-Michel Coindre, et al.
  Pubblicazione: (2023-11-01)